Kbi-110 - [better]

Hardware interrupts are fast—so fast they’ll "see" the mechanical bouncing of a physical switch. Always include a small software delay or state check in your ISR (Interrupt Service Routine).

KBI-110 isn't a cure yet, and it isn't on the market. But it is a perfect lens through which to view the evolution of cancer treatment. We have moved from "kill everything" (chemotherapy) to "release the brakes" (checkpoint inhibitors) to "manually steer the attack" (bispecifics). KBI-110

| Model | Outcome | |---|---| | | 78 % reduction in PASI‑like scores at 5 mg kg⁻¹ PO | | Rat collagen‑induced arthritis | Dose‑dependent decrease in joint swelling; comparable to tofacitinib at 0.5× dose | | Safety Pharmacology | No significant QTc prolongation (hERG IC₅₀ > 30 µM) | | Genotoxicity | Negative Ames, mouse lymphoma assay | | Toxicology | 6‑month GLP repeat‑dose study in dogs: NOAEL 30 mg kg⁻¹/day (≈ 10× projected clinical exposure) | Hardware interrupts are fast—so fast they’ll "see" the

The pyridyl‑urea arm of KBI‑110 weakly recruits the E3 ligase CRBN . While the affinity is insufficient for robust degradation on its own, in cells where BRD9 is over‑expressed (e.g., AML blasts), the ternary complex forms long enough to ubiquitinate and partially degrade BRD9. This results in a dose‑dependent, partial knock‑down (≈ 30‑40 % reduction at 100 nM), which is enough to blunt pathogenic transcription without fully erasing the protein’s physiological function. But it is a perfect lens through which